Martin brings over 30 years of business experience, many of which have been spent at the interface between commercial and development, including numerous product launches in pharmaceuticals, vaccines and gene therapy. In his most recent role as Senior Vice President, Rare Diseases at GlaxoSmithKline, he led an integrated Global R&D and Commercial team spanning Pulmonary Arterial Hypertension, Systemic Amyloidosis, and autologous ex vivo gene therapy for a range of ultra-orphan diseases which included the Global Rare Diseases Unit. He his role, Martin oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. Furthermore, under his leadership, GlaxoSmithKline transferred its gene therapy portfolio to Orchard Therapeutics (where he also served as a Board member). Prior to that, during his time leading the commercial organisation at GSK Vaccines, Martin developed the growth strategy and transformed the commercial capability in the Vaccines division. His expertise will help guide our strategic direction and maximise our growth opportunities. Martin has a degree in Biology.